Prior Auth Required

00626 - https://www.nature.com/articles/d43747-020- -y

This procedure appears on the selected insurer prior authorization source.

Check another codeExplore policy data
Prior authorizationPrior Auth Required
Procedure / Servicehttps://www.nature.com/articles/d43747-020- -y
Procedure / Service Description

1 Yu CY, et al. Complement inhibitor for therapy of CHAPLE. Nat Immunol. 2021 Feb; 22(2):106-108. 2/21 8/23 - 2 Nature Journal. Methods of Diagnosing and Treating CHAPLE, A Newly Identified Orphan Disease: 8/23 Collaborative Research and Licensing Opportunity article. Available at: https://www.nature.com/articles/d43747-020-00626-y 3 Medical Professionals Reference - FDA Greenlights Veopoz, the First Treatment for CHAPLE Disease 8/23 8/23 (online article). Published August 21, 2023. Available at: https://www.empr.com/home/news/fda-

Likely documents
  • Confirm benefit details
  • Submit clinical notes if requested by the plan
Next actions
  • Confirm the current plan policy before submission.
  • Use the insurer authorization workflow for this listed code.